07.05.2024 21:19:23
|
EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024
EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Change in Forecast Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024
Fresenius raises its full-year outlook due to the excellent first quarter and a better than originally expected operating performance for the remainder of the fiscal year 2024. Fresenius now expects organic group revenue growth between 4 and 7% for the fiscal year 2024 (previously: 3 to 6%). Group EBIT at constant currency is now expected to grow between 6 and 10% (previously: 4 to 8%). The increase of the group outlook is based on improved business prospects for Fresenius Kabi. Fresenius Kabi now expects organic revenue growth in the mid to high single-digit percentage range for fiscal year 2024 (previously: mid single-digit percentage range). The EBIT margin is now expected to range between 15 and 16% (previously: around 15%). The adjustment of the group outlook also reflects the fact that the forecast is now provided without Fresenius Vamed, i.e. exclusively for the operating companies Fresenius Kabi and Fresenius Helios. Following the announcement of the planned divestment of Fresenius Vamed’s rehabilitation business, Fresenius has initiated its structured exit from its investment company Fresenius Vamed. For additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures. Fresenius SE & Co. KGaA, represented by Fresenius Management SE, The Management Board Bad Homburg v.d.H., May 7, 2024 ---------------------------------------- Contact: Markus Georgi Senior Vice President Investor Relations T: +49 (0) 6172 608-2485 markus.georgi@fresenius.com ---------------------------------------- End of Note End of Inside Information
07-May-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Fresenius SE & Co. KGaA |
Else-Kröner-Straße 1 | |
61352 Bad Homburg v.d.H. | |
Germany | |
Phone: | +49 (0)6172 608-2485 |
Fax: | +49 (0)6172 608-2488 |
E-mail: | ir-fre@fresenius.com |
Internet: | www.fresenius.com |
ISIN: | DE0005785604 |
WKN: | 578560 |
Indices: | DAX |
Listed: | Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange |
EQS News ID: | 1898031 |
End of Announcement | EQS News Service |
|
1898031 07-May-2024 CET/CEST
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Fresenius SE & Co. KGaA (St.)mehr Nachrichten
23.12.24 |
XETRA-Handel LUS-DAX schwächelt zum Ende des Montagshandels (finanzen.at) | |
23.12.24 |
Schwache Performance in Frankfurt: DAX zum Handelsende in Rot (finanzen.at) | |
20.12.24 |
Fresenius Kabi vermarktet Eylea-Biosimilar in USA und Lateinamerika (Dow Jones) | |
20.12.24 |
Angespannte Stimmung in Frankfurt: LUS-DAX liegt zum Handelsstart im Minus (finanzen.at) | |
20.12.24 |
XETRA-Handel DAX sackt zum Start des Freitagshandels ab (finanzen.at) | |
17.12.24 |
LUS-DAX-Handel aktuell: LUS-DAX präsentiert sich zum Handelsende leichter (finanzen.at) | |
17.12.24 |
Schwacher Wochentag in Frankfurt: DAX gibt schlussendlich nach (finanzen.at) | |
17.12.24 |
Starker Wochentag in Frankfurt: mittags Pluszeichen im DAX (finanzen.at) |
Analysen zu Fresenius SE & Co. KGaA (St.)mehr Analysen
11.12.24 | Fresenius Buy | Jefferies & Company Inc. | |
03.12.24 | Fresenius Overweight | JP Morgan Chase & Co. | |
26.11.24 | Fresenius Buy | UBS AG | |
21.11.24 | Fresenius Overweight | Barclays Capital | |
20.11.24 | Fresenius Kaufen | DZ BANK |